tiprankstipranks
Trending News
More News >
Avidity Biosciences Inc (RNA)
NASDAQ:RNA
US Market

Avidity Biosciences (RNA) Stock Forecast & Price Target

Compare
793 Followers
See the Price Targets and Ratings of:

RNA Analyst Ratings

Strong Buy
16Ratings
Strong Buy
16 Buy
0 Hold
0 Sell
Based on 16 analysts giving stock ratings to
Avidity
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RNA Stock 12 Month Forecast

Average Price Target

$67.06
▲(124.81%Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Avidity Biosciences in the last 3 months. The average price target is $67.06 with a high forecast of $96.00 and a low forecast of $50.00. The average price target represents a 124.81% change from the last price of $29.83.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","43":"$43","61":"$61","79":"$79","97":"$97"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$96.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$67.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,43,61,79,97],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.17,38.003076923076925,42.83615384615385,47.669230769230765,52.502307692307696,57.33538461538461,62.168461538461536,67.00153846153846,71.83461538461538,76.6676923076923,81.50076923076924,86.33384615384615,91.16692307692307,{"y":96,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.17,35.776923076923076,38.38384615384616,40.99076923076923,43.59769230769231,46.20461538461539,48.81153846153846,51.41846153846154,54.02538461538462,56.63230769230769,59.23923076923077,61.84615384615385,64.45307692307692,{"y":67.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.17,34.464615384615385,35.75923076923077,37.05384615384615,38.34846153846154,39.643076923076926,40.93769230769231,42.23230769230769,43.526923076923076,44.821538461538466,46.11615384615385,47.41076923076923,48.70538461538462,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.86,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.28,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.57,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.87,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.08,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$96.00Average Price Target$67.06Lowest Price Target$50.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on RNA
TipRanks AITipRanks
Not Ranked
TipRanks
$32
Hold
7.27%
Upside
Reiterated
06/14/25
Avidity Biosciences' stock score is primarily driven by promising corporate developments in clinical trials, which strengthen its growth prospects. However, financial performance, including profitability and cash flow challenges, and a weak valuation due to negative earnings, weigh down the overall score.
Cantor Fitzgerald Analyst forecast on RNA
Eric Schmidt FCACantor Fitzgerald
Cantor Fitzgerald
$96
Buy
221.82%
Upside
Reiterated
06/27/25
Cantor Fitzgerald Reaffirms Their Buy Rating on Avidity Biosciences (RNA)
TD Cowen Analyst forecast on RNA
Ritu BaralTD Cowen
TD Cowen
$78
Buy
161.48%
Upside
Reiterated
06/24/25
Avidity Biosciences (RNA) Gets a Buy from TD Cowen
Barclays Analyst forecast on RNA
Gena WangBarclays
Barclays
$59
Buy
97.79%
Upside
Reiterated
06/23/25
Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (NASDAQ: RNA) and Exelixis (NASDAQ: EXEL)
Bernstein
$50
Buy
67.62%
Upside
Initiated
06/23/25
Avidity Biosciences (RNA) Has a New Rating from Bernstein
Bank of America Securities Analyst forecast on RNA
Tazeen AhmadBank of America Securities
Bank of America Securities
$54
Buy
81.03%
Upside
Reiterated
06/17/25
Avidity Biosciences Positioned for Market Leadership with Promising DM1 Treatment in Phase 3 Trial
Wells Fargo Analyst forecast on RNA
Yanan ZhuWells Fargo
Wells Fargo
$70
Buy
134.66%
Upside
Reiterated
06/17/25
Avidity Biosciences: Strong Market Position and Future Potential Justify Buy Rating
Wolfe Research Analyst forecast on RNA
Andy ChenWolfe Research
Wolfe Research
$55
Buy
84.38%
Upside
Initiated
06/16/25
Avidity Biosciences initiated with an Outperform at Wolfe ResearchAvidity Biosciences initiated with an Outperform at Wolfe Research
Leerink Partners Analyst forecast on RNA
Joseph SchwartzLeerink Partners
Leerink Partners
$60$65
Buy
117.90%
Upside
Reiterated
06/13/25
Avidity Biosciences price target raised to $65 from $60 at LeerinkAvidity Biosciences price target raised to $65 from $60 at Leerink
Raymond James Analyst forecast on RNA
Martin AusterRaymond James
Raymond James
$65
Buy
117.90%
Upside
Initiated
06/10/25
Avidity Biosciences initiated with a Strong Buy at Raymond JamesAvidity Biosciences initiated with a Strong Buy at Raymond James
Citi
$70$75
Buy
151.42%
Upside
Reiterated
06/10/25
Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (NASDAQ: RNA), Danaher (NYSE: DHR) and Ascendis Pharma (NASDAQ: ASND)
Scotiabank Analyst forecast on RNA
Louise ChenScotiabank
Scotiabank
$70
Buy
134.66%
Upside
Reiterated
06/10/25
Avidity Biosciences (RNA) Receives a Buy from Scotiabank
Needham
$60
Buy
101.14%
Upside
Reiterated
06/09/25
Avidity Biosciences Receives Buy Rating Due to Promising FSHD Program Developments and Accelerated FDA Approval Pathway
Chardan Capital Analyst forecast on RNA
Keay NakaeChardan Capital
Chardan Capital
$75
Buy
151.42%
Upside
Reiterated
06/09/25
Analysts' Top Healthcare Picks: Amicus (FOLD), Inspire Medical Systems (INSP)
H.C. Wainwright Analyst forecast on RNA
Ananda GhoshH.C. Wainwright
H.C. Wainwright
$68
Buy
127.96%
Upside
Reiterated
06/09/25
Avidity data strengthens accelerated approval case, says H.C. WainwrightAvidity data strengthens accelerated approval case, says H.C. Wainwright
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on RNA
TipRanks AITipRanks
Not Ranked
TipRanks
$32
Hold
7.27%
Upside
Reiterated
06/14/25
Avidity Biosciences' stock score is primarily driven by promising corporate developments in clinical trials, which strengthen its growth prospects. However, financial performance, including profitability and cash flow challenges, and a weak valuation due to negative earnings, weigh down the overall score.
Cantor Fitzgerald Analyst forecast on RNA
Eric Schmidt FCACantor Fitzgerald
Cantor Fitzgerald
$96
Buy
221.82%
Upside
Reiterated
06/27/25
Cantor Fitzgerald Reaffirms Their Buy Rating on Avidity Biosciences (RNA)
TD Cowen Analyst forecast on RNA
Ritu BaralTD Cowen
TD Cowen
$78
Buy
161.48%
Upside
Reiterated
06/24/25
Avidity Biosciences (RNA) Gets a Buy from TD Cowen
Barclays Analyst forecast on RNA
Gena WangBarclays
Barclays
$59
Buy
97.79%
Upside
Reiterated
06/23/25
Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (NASDAQ: RNA) and Exelixis (NASDAQ: EXEL)
Bernstein
$50
Buy
67.62%
Upside
Initiated
06/23/25
Avidity Biosciences (RNA) Has a New Rating from Bernstein
Bank of America Securities Analyst forecast on RNA
Tazeen AhmadBank of America Securities
Bank of America Securities
$54
Buy
81.03%
Upside
Reiterated
06/17/25
Avidity Biosciences Positioned for Market Leadership with Promising DM1 Treatment in Phase 3 Trial
Wells Fargo Analyst forecast on RNA
Yanan ZhuWells Fargo
Wells Fargo
$70
Buy
134.66%
Upside
Reiterated
06/17/25
Avidity Biosciences: Strong Market Position and Future Potential Justify Buy Rating
Wolfe Research Analyst forecast on RNA
Andy ChenWolfe Research
Wolfe Research
$55
Buy
84.38%
Upside
Initiated
06/16/25
Avidity Biosciences initiated with an Outperform at Wolfe ResearchAvidity Biosciences initiated with an Outperform at Wolfe Research
Leerink Partners Analyst forecast on RNA
Joseph SchwartzLeerink Partners
Leerink Partners
$60$65
Buy
117.90%
Upside
Reiterated
06/13/25
Avidity Biosciences price target raised to $65 from $60 at LeerinkAvidity Biosciences price target raised to $65 from $60 at Leerink
Raymond James Analyst forecast on RNA
Martin AusterRaymond James
Raymond James
$65
Buy
117.90%
Upside
Initiated
06/10/25
Avidity Biosciences initiated with a Strong Buy at Raymond JamesAvidity Biosciences initiated with a Strong Buy at Raymond James
Citi
$70$75
Buy
151.42%
Upside
Reiterated
06/10/25
Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (NASDAQ: RNA), Danaher (NYSE: DHR) and Ascendis Pharma (NASDAQ: ASND)
Scotiabank Analyst forecast on RNA
Louise ChenScotiabank
Scotiabank
$70
Buy
134.66%
Upside
Reiterated
06/10/25
Avidity Biosciences (RNA) Receives a Buy from Scotiabank
Needham
$60
Buy
101.14%
Upside
Reiterated
06/09/25
Avidity Biosciences Receives Buy Rating Due to Promising FSHD Program Developments and Accelerated FDA Approval Pathway
Chardan Capital Analyst forecast on RNA
Keay NakaeChardan Capital
Chardan Capital
$75
Buy
151.42%
Upside
Reiterated
06/09/25
Analysts' Top Healthcare Picks: Amicus (FOLD), Inspire Medical Systems (INSP)
H.C. Wainwright Analyst forecast on RNA
Ananda GhoshH.C. Wainwright
H.C. Wainwright
$68
Buy
127.96%
Upside
Reiterated
06/09/25
Avidity data strengthens accelerated approval case, says H.C. WainwrightAvidity data strengthens accelerated approval case, says H.C. Wainwright
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Avidity Biosciences

1 Month
xxx
Success Rate
13/23 ratings generated profit
57%
Average Return
+3.23%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 56.52% of your transactions generating a profit, with an average return of +3.23% per trade.
3 Months
xxx
Success Rate
8/14 ratings generated profit
57%
Average Return
+9.41%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +9.41% per trade.
1 Year
Yanan ZhuWells Fargo
Success Rate
12/23 ratings generated profit
52%
Average Return
+110.66%
reiterated a buy rating 11 days ago
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 52.17% of your transactions generating a profit, with an average return of +110.66% per trade.
2 Years
xxx
Success Rate
17/24 ratings generated profit
71%
Average Return
+100.20%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 70.83% of your transactions generating a profit, with an average return of +100.20% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RNA Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
17
29
25
26
31
Buy
1
2
1
1
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
31
26
27
31
In the current month, RNA has received 31 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RNA average Analyst price target in the past 3 months is 67.06.
Each month's total comprises the sum of three months' worth of ratings.

RNA Financial Forecast

RNA Earnings Forecast

Next quarter’s earnings estimate for RNA is -$0.95 with a range of -$1.33 to -$0.55. The previous quarter’s EPS was -$0.90. RNA beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.17% of the time in the same period. In the last calendar year RNA has Outperformed its overall industry.
Next quarter’s earnings estimate for RNA is -$0.95 with a range of -$1.33 to -$0.55. The previous quarter’s EPS was -$0.90. RNA beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.17% of the time in the same period. In the last calendar year RNA has Outperformed its overall industry.

RNA Sales Forecast

Next quarter’s sales forecast for RNA is $1.48M with a range of $0.00 to $3.89M. The previous quarter’s sales results were $1.57M. RNA beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.47% of the time in the same period. In the last calendar year RNA has Outperformed its overall industry.
Next quarter’s sales forecast for RNA is $1.48M with a range of $0.00 to $3.89M. The previous quarter’s sales results were $1.57M. RNA beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.47% of the time in the same period. In the last calendar year RNA has Outperformed its overall industry.

RNA Stock Forecast FAQ

What is RNA’s average 12-month price target, according to analysts?
Based on analyst ratings, Avidity Biosciences Inc’s 12-month average price target is 67.06.
    What is RNA’s upside potential, based on the analysts’ average price target?
    Avidity Biosciences Inc has 124.81% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RNA a Buy, Sell or Hold?
          Avidity Biosciences Inc has a consensus rating of Strong Buy which is based on 16 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Avidity Biosciences Inc’s price target?
            The average price target for Avidity Biosciences Inc is 67.06. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $96.00 ,the lowest forecast is $50.00. The average price target represents 124.81% Increase from the current price of $29.83.
              What do analysts say about Avidity Biosciences Inc?
              Avidity Biosciences Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of RNA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis